🚀 VC round data is live in beta, check it out!
BioRegenx Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioRegenx and similar public comparables like PMGC Holdings, Pharmena, Arctic Bioscience, Airway Medix and more.
BioRegenx Overview
About BioRegenx
BioRegenx Inc develops and manufactures medical test equipment and high-quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel to health professionals and research organizations. The company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. The Company focuses on commercialization of its patented technologies in its field.
Founded
1998
HQ
Employees
10
Website
Financials (FY)
EV
$13M
BioRegenx Financials
BioRegenx reported last fiscal year revenue of $2M and negative EBITDA of ($21M).
In the same fiscal year, BioRegenx generated $2M in gross profit, ($21M) in EBITDA losses, and had net loss of ($23M).
BioRegenx P&L
In the most recent fiscal year, BioRegenx reported revenue of $2M and EBITDA of ($21M).
BioRegenx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $2M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 71% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($21M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (878%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (280%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($23M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (985%) | XXX | XXX | XXX |
| Net Debt | — | — | $2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioRegenx Stock Performance
BioRegenx has current market cap of $11M, and enterprise value of $13M.
Market Cap Evolution
BioRegenx's stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $11M | 0.0% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioRegenx Valuation Multiples
BioRegenx trades at 5.6x EV/Revenue multiple, and (0.6x) EV/EBITDA.
BioRegenx Financial Valuation Multiples
As of April 11, 2026, BioRegenx has market cap of $11M and EV of $13M.
Equity research analysts estimate BioRegenx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioRegenx has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (2.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.9x | XXX | XXX | XXX |
| P/E | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (25.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioRegenx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioRegenx Margins & Growth Rates
BioRegenx's revenue in the last fiscal year grew by 10421%.
BioRegenx's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.
BioRegenx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 10421% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (878%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 3589% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 250% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 351% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioRegenx Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals and Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PMGC Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmena | XXX | XXX | XXX | XXX | XXX | XXX |
| Arctic Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Airway Medix | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioRegenx M&A Activity
BioRegenx acquired XXX companies to date.
Last acquisition by BioRegenx was on XXXXXXXX, XXXXX. BioRegenx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioRegenx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioRegenx Investment Activity
BioRegenx invested in XXX companies to date.
BioRegenx made its latest investment on XXXXXXXX, XXXXX. BioRegenx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioRegenx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioRegenx
| When was BioRegenx founded? | BioRegenx was founded in 1998. |
| Where is BioRegenx headquartered? | BioRegenx is headquartered in United States. |
| How many employees does BioRegenx have? | As of today, BioRegenx has over 10 employees. |
| Is BioRegenx publicly listed? | Yes, BioRegenx is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of BioRegenx? | BioRegenx trades under BRGX ticker. |
| Who are competitors of BioRegenx? | BioRegenx main competitors are PMGC Holdings, Pharmena, Arctic Bioscience, Airway Medix. |
| What is the current market cap of BioRegenx? | BioRegenx's current market cap is $11M. |
| What is the current revenue of BioRegenx? | BioRegenx's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of BioRegenx? | Current revenue multiple of BioRegenx is 5.6x. |
| Is BioRegenx profitable? | No, BioRegenx is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.